GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (STU:4B70) » Definitions » Cyclically Adjusted Book per Share

Antibe Therapeutics (STU:4B70) Cyclically Adjusted Book per Share : €1.65 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Antibe Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was €0.337. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.65 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Antibe Therapeutics's average Cyclically Adjusted Book Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-17), Antibe Therapeutics's current stock price is €2.44. Antibe Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €1.65. Antibe Therapeutics's Cyclically Adjusted PB Ratio of today is 1.48.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Antibe Therapeutics was 1.84. The lowest was 0.00. And the median was 0.00.


Antibe Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Antibe Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Cyclically Adjusted Book per Share Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.67 2.52

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.01 2.52 3.34 3.14 1.65

Competitive Comparison of Antibe Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Antibe Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Cyclically Adjusted PB Ratio falls into.



Antibe Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Antibe Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.337/125.0724*125.0724
=0.337

Current CPI (Dec. 2023) = 125.0724.

Antibe Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.618 98.604 0.784
201406 0.535 99.473 0.673
201409 0.334 99.394 0.420
201412 0.179 98.367 0.228
201503 0.067 99.789 0.084
201506 0.167 100.500 0.208
201509 0.064 100.421 0.080
201512 0.450 99.947 0.563
201603 0.343 101.054 0.425
201606 0.382 102.002 0.468
201609 0.302 101.765 0.371
201612 0.331 101.449 0.408
201703 0.220 102.634 0.268
201706 0.242 103.029 0.294
201709 0.202 103.345 0.244
201712 0.133 103.345 0.161
201803 0.252 105.004 0.300
201806 0.243 105.557 0.288
201809 0.196 105.636 0.232
201812 0.169 105.399 0.201
201903 0.202 106.979 0.236
201906 0.146 107.690 0.170
201909 0.227 107.611 0.264
201912 0.168 107.769 0.195
202003 0.083 107.927 0.096
202006 0.523 108.401 0.603
202009 0.377 108.164 0.436
202012 0.280 108.559 0.323
202103 0.735 110.298 0.833
202106 0.944 111.720 1.057
202109 0.836 112.905 0.926
202112 0.816 113.774 0.897
202203 0.782 117.646 0.831
202206 0.738 120.806 0.764
202209 0.679 120.648 0.704
202212 0.573 120.964 0.592
202303 0.521 122.702 0.531
202306 0.459 124.203 0.462
202309 0.391 125.230 0.391
202312 0.337 125.072 0.337

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Antibe Therapeutics  (STU:4B70) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Antibe Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.44/1.65
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Antibe Therapeutics was 1.84. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Antibe Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (STU:4B70) Business Description

Industry
Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Antibe Therapeutics (STU:4B70) Headlines

No Headlines